A Study of NDI 1150-101 in Patients With Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

November 5, 2021

Primary Completion Date

February 28, 2025

Study Completion Date

May 31, 2025

Conditions
Solid TumorRenal Cell Carcinoma (Kidney Cancer)Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaNon-Small Cell Lung Cancer
Interventions
DRUG

NDI-101150

NDI-101150 capsules

DRUG

Pembrolizumab

Pembrolizumab IV infusion

Trial Locations (19)

10032

Columbia University Irving Medical Center, New York

21201

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore

22031

NEXT Oncology, Fairfax

34474

Ocala Oncology Center, Ocala

40202

Norton Cancer Institute, Louisville

48202

Henry Ford Cancer, Detroit

53705

University of Wisconsin, Madison

55101

HealthPartners Cancer Research Center, Saint Paul

63110

Washington University, St Louis

73104

Stephenson Cancer Center, Oklahoma City

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

77030

Center for Oncology and Blood Disorders, Houston

Oncology Consultants, Houston

78229

NEXT Oncology, San Antonio

85258

Honor Health Research Institute, Scottsdale

98405

Northwest Medical Specialties, Tacoma

06520

Yale Cancer Center, New Haven

20007-2113

Georgetown University, Washington D.C.

07601

Hackensack University, Hackensack

All Listed Sponsors
lead

Nimbus Saturn, Inc.

INDUSTRY